What can help after you know the cause?

What can I do at home?

Change whichever reach, lift, serve, or sleep position brings on the ache. Keep using the arm where it moves without a sharp flare.

Give that change a fair stretch of time. Shoulders don’t always answer after a few careful days.

A guided strengthening plan may help you build the load back slowly, with room to change the pace when your shoulder stays sore later that day or wakes you again at night. It doesn’t have to be forced.

What if simple care hasn’t been enough?

A clinician may discuss medicine, cortisone, more focused therapy, or an operation. Each choice depends on the cause, the time course, and your health.

Cortisone can bring short relief for some people, but it doesn’t repair a torn tendon. Surgery has a place after some injuries and for selected tears.

One operation that makes more room above the cuff hasn’t beaten a look-alike operation in careful trials. That’s why the exact operation matters as much as the word surgery.

What does QC Kinetix provide?

Among the non-surgical choices at QC Kinetix are regenerative treatments for joint soreness. Depending on your visit, they may include PRP or concentrated PRP made from your own blood.

These are biologic therapies, and results vary. They’re discussed as options, not as a promise to rebuild your tendon or worn joint.

A medical provider first listens, examines your shoulder, and reviews any useful images. You can then weigh the likely fit, cost, limits, and other paths without being rushed.

Sources

1. In the MOON Shoulder prospective cohort of 452 patients with symptomatic, ATRAUMATIC full-thickness rotator cuff tears, physical therapy succeeded in more than 70% of patients at 10 years: only 115 (27.0%) had surgery at any point over the decade. Patient-reported outcomes improved with physical therapy and did NOT decline over 10 years in those who never had surgery. The strongest predictor of early surgery was low patient expectation of physical therapy, not tear anatomy.

   Kuhn JE, et al. — The Predictors of Surgery for Symptomatic, Atraumatic Full-Thickness Rotator Cuff Tears Change Over Time: Ten-Year Outcomes of the MOON Shoulder Prospective Cohort.. J Bone Joint Surg Am, 2024. DOI: 10.2106/JBJS.23.00978.

2. The GRASP trial randomized 708 adults with a rotator cuff disorder to progressive exercise (up to 6 sessions), a single best-practice advice session, or either of those preceded by a corticosteroid injection. Over 12 months there was no evidence of a difference in Shoulder Pain and Disability Index between progressive exercise and one advice session (adjusted mean difference -0.66, 99% CI -4.52 to 3.20), and no evidence of a difference between having a corticosteroid injection and not having one.

   Hopewell S, et al. — Progressive exercise compared with best practice advice, with or without corticosteroid injection, for the treatment of patients with rotator cuff disorders (GRASP): a multicentre, pragmatic, 2 × 2 factorial, randomised controlled trial.. Lancet, 2021. DOI: 10.1016/S0140-6736(21)00846-1.

3. The Cochrane review of manual therapy and exercise for rotator cuff disease included 60 trials and 3,620 participants but could perform no meta-analysis because of clinical heterogeneity and incomplete outcome reporting; risk of bias was high in 43 of the 60 trials. The single high-quality placebo-controlled trial (120 participants) found manual therapy plus exercise no better than inactive ultrasound at 22 weeks on overall pain.

   Page MJ, et al. — Manual therapy and exercise for rotator cuff disease.. Cochrane Database Syst Rev, 2016. DOI: 10.1002/14651858.CD012224.

4. FDA states verbatim that stem cell, stromal vascular fraction, umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products 'have [not] been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells from umbilical cord blood, approved only for disorders of blood production, and there are currently NO FDA-approved exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2020.

5. A 2026 meta-analysis of 10 randomized trials (n=591) found PRP and corticosteroid indistinguishable at 3-6 weeks and 3 months, with PRP pulling ahead at 6 months: ASES +10.8 (95% CI 4.71-16.80), Constant-Murley +10.7 (1.21-20.27) and VAS pain -0.8 (-1.45 to -0.18), plus fewer adverse events (RR 0.66, 0.44-0.99). The authors describe the benefit as statistically significant but CLINICALLY MODEST.

   Yuwarungsikul C, et al. — Platelet-rich plasma provides modest but durable functional benefit over corticosteroid for rotator cuff tendinopathy: A systematic review and meta-analysis of randomized controlled trials.. Knee Surg Sports Traumatol Arthrosc, 2026. DOI: 10.1002/ksa.70416.

6. A meta-analysis of nine randomized trials (469 patients) found corticosteroid superior to PRP in the SHORT term on Constant, Simple Shoulder Test and ASES scores, no difference at mid-term, and PRP superior in the LONG term on Simple Shoulder Test and ASES. The authors state explicitly that none of these differences reached the minimal clinically important difference.

   Peng Y, et al. — Comparison of the effects of platelet-rich plasma and corticosteroid injection in rotator cuff disease treatment: a systematic review and meta-analysis.. J Shoulder Elbow Surg, 2023. DOI: 10.1016/j.jse.2023.01.037.

7. The August 2025 AAOS Evidence-Based Clinical Practice Guideline on Management of Rotator Cuff Injuries issued 25 recommendations and 4 consensus statements. Among its updates it clearly RESTRICTS the use of platelet-rich plasma and marrow stimulation in rotator cuff repair, limits prolotherapy in full-thickness tears, establishes CT as an adjunctive imaging modality, and endorses early mobilization after repair of small-to-medium tears.

   Ye Y, et al. — [Interpretation of the 2025 American Academy of Orthopaedic Surgeons (AAOS) on Management of Rotator Cuff Injuries Evidence-Based Clinical Practice Guideline].. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, 2026. DOI: 10.7507/1002-1892.202511084.

8. CSAW randomized 313 UK patients with at least 3 months of subacromial pain, intact cuff tendons and a failed non-operative programme to decompression surgery, placebo arthroscopy, or no treatment. Mean Oxford Shoulder Score at 6 months did not differ between the two surgical groups (32.7 versus 34.2; mean difference -1.3, 95% CI -3.9 to 1.3, p=0.31), meaning the bone-and-soft-tissue removal that defines the operation added nothing.

   Beard DJ, et al. — Arthroscopic subacromial decompression for subacromial shoulder pain (CSAW): a multicentre, pragmatic, parallel group, placebo-controlled, three-group, randomised surgical trial.. Lancet, 2018. DOI: 10.1016/S0140-6736(17)32457-1.

9. At 10 years, arthroscopic subacromial decompression offered NO benefit over placebo surgery for subacromial pain syndrome: the mean difference in VAS pain was -1.5 points (95% CI -8.6 to 5.6) at rest and -3.2 points (-13.0 to 6.5) on arm activity, against a minimally important difference of 15. It also showed no benefit over exercise therapy.

   Kanto K, et al. — Arthroscopic subacromial decompression versus placebo surgery for subacromial pain syndrome: 10 year follow-up of the FIMPACT randomised, placebo surgery controlled trial.. BMJ, 2025. DOI: 10.1136/bmj-2025-086201.

10. A comparative longitudinal study of 83 non-operatively managed and 65 surgically repaired degenerative rotator cuff tears, matched at baseline for tear width, length and fatty degeneration, found significantly better final outcomes in the surgical group: median VAS pain 0 versus 3.5, composite ASES 95 versus 65.8, abduction strength 69.6 N versus 35.9 N, and greater forward elevation and external rotation (all p<=0.002). The groups were not randomized - the surgical group had failed non-operative treatment and was younger.

    Hill JR, et al. — Does surgical intervention alter the natural history of degenerative rotator cuff tears? Comparative analysis from a prospective longitudinal study.. J Shoulder Elbow Surg, 2025. DOI: 10.1016/j.jse.2024.05.056.

11. UK FROST randomized 503 adults with primary frozen shoulder to manipulation under anaesthesia, arthroscopic capsular release, or early structured physiotherapy with steroid injection. At 12 months every between-group difference on the Oxford Shoulder Score was smaller than the target difference, so NONE of the three was clinically superior. Capsular release carried the most serious adverse events (8 versus 2 with manipulation), and manipulation under anaesthesia was the most cost-effective.

    Rangan A, et al. — Management of adults with primary frozen shoulder in secondary care (UK FROST): a multicentre, pragmatic, three-arm, superiority randomised clinical trial.. Lancet, 2020. DOI: 10.1016/S0140-6736(20)31965-6.